Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus

The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. Alogliptin is efficacious both as monotherapy and as add-on/combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Kisanuki, Koichi, Shibata, Mari, Oohira, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834733/
https://www.ncbi.nlm.nih.gov/pubmed/31654243
http://dx.doi.org/10.1007/s40264-019-00857-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834733/
https://www.ncbi.nlm.nih.gov/pubmed/31654243
http://dx.doi.org/10.1007/s40264-019-00857-8

Ejemplares similares